School of Nursing and Midwifery, Clarke International University, PO Box 7782, Kampala, Uganda.
Uganda Cancer Institute, PO Box 3935, Kampala, Uganda.
BMC Cancer. 2023 Jul 5;23(1):631. doi: 10.1186/s12885-023-11145-1.
Cervical cancer is one of the most common cancers and a major cause of morbidity among women globally. Chemoradiation therapy is the preferred standard treatment for women with stage IB to IVA. However, the benefits of this treatment can only be achieved if patients adhere to the treatment guidelines. In this study, the proportion of compliance or adherence to chemo-radiation treatment among cervical cancer patients at Uganda Cancer Institute (UCI) was determined.
This was a cross-sectional study that reviewed data retrospectively for 196 cervical cancer patients who were prescribed to chemo-radiation therapy at UCI between November 2020 to May 2021, having been diagnosed with disease stage IB to IVA. Patient data and information on treatment uptake was obtained by review of the patient's medical records. Treatment compliance was determined by calculating the number of participants who completed the prescribed treatment (definitive pelvic concurrent chemoradiation to 50 Gy external beam radiotherapy with weekly concurrent cisplatin followed by intracavitary brachytherapy 24 Gy in 3 fractions at 8 Gy once a week over 3 weeks). Associations between patient factors and treatment adherence were determined using logistic regression analysis. In all statistical tests, a P- value of < 0.05 was considered as significant.
The proportion of patients who were administered with external beam radiation (EBRT), chemotherapy and brachytherapy were 82.6%, 52.04% and 66.2% respectively. However, only 23 of 196 patients (11.7%) were found to have adhered to the treatment plan by completion of all definitive pelvic concurrent chemoradiation to 50 Gy external beam radiotherapy (5 weeks) with weekly concurrent cisplatin (5 cycles) followed by intracavitary brachytherapy 24 Gy in 3 fractions at 8 Gy once a week over 3 weeks (3 sessions). There were no significant associations between patient factors and treatment adherence after multivariable analysis.
Treatment compliance was found in only 12% of the cohort participants. No association of patient factors with treatment compliance was found. Additional studies on treatment adherence with larger sample sizes are needed to confirm the associations.
宫颈癌是最常见的癌症之一，也是全球女性发病率的主要原因。化学放疗是 IB 期至 IVA 期女性的首选标准治疗方法。然而，只有患者遵守治疗指南，才能获得这种治疗的益处。在这项研究中，确定了乌干达癌症研究所（UCI）宫颈癌患者接受化疗放疗的比例。
这是一项回顾性的横断面研究，对 2020 年 11 月至 2021 年 5 月在 UCI 接受化疗放疗的 196 名宫颈癌患者的数据进行了回顾。这些患者被诊断为 IB 期至 IVA 期疾病。通过查阅患者病历获得患者数据和治疗情况。通过计算完成规定治疗（5 周内完成 50 Gy 外照射盆腔同期顺铂化疗，随后在 3 周内每周进行 8 Gy 腔内近距离治疗 3 次，共 24 Gy）的患者人数来确定治疗依从性。使用逻辑回归分析确定患者因素与治疗依从性之间的关联。在所有统计检验中，P 值<0.05 被认为具有统计学意义。
接受外照射放疗（EBRT）、化疗和近距离放疗的患者比例分别为 82.6%、52.04%和 66.2%。然而，只有 196 名患者中的 23 名（11.7%）通过完成所有规定的盆腔同期顺铂化疗（5 周）至 50 Gy 外照射放疗（5 周）、每周同期顺铂（5 个周期）以及随后的腔内近距离放疗 24 Gy （3 周内每周 1 次，每次 8 Gy，共 3 次），达到了治疗计划的要求。多变量分析后，患者因素与治疗依从性之间无显著关联。
只有 12%的队列参与者符合治疗标准。没有发现患者因素与治疗依从性之间的关联。需要进行更多的研究，以更大的样本量来证实这些关联。
